[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1014935A1 - Substituted benzylaminopiperidine compounds - Google Patents

Substituted benzylaminopiperidine compounds

Info

Publication number
HK1014935A1
HK1014935A1 HK98119203A HK98119203A HK1014935A1 HK 1014935 A1 HK1014935 A1 HK 1014935A1 HK 98119203 A HK98119203 A HK 98119203A HK 98119203 A HK98119203 A HK 98119203A HK 1014935 A1 HK1014935 A1 HK 1014935A1
Authority
HK
Hong Kong
Prior art keywords
compounds
substituted
substituted benzylaminopiperidine
benzylaminopiperidine compounds
benzylaminopiperidine
Prior art date
Application number
HK98119203A
Other languages
English (en)
Inventor
Kunio Satake
Yuji Shishido
Hiroaki Wakabayashi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HK1014935A1 publication Critical patent/HK1014935A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK98119203A 1995-08-24 1998-12-30 Substituted benzylaminopiperidine compounds HK1014935A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24
PCT/IB1996/000572 WO1997008144A1 (en) 1995-08-24 1996-06-10 Substituted benzylaminopiperidine compounds

Publications (1)

Publication Number Publication Date
HK1014935A1 true HK1014935A1 (en) 1999-10-08

Family

ID=11004362

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98119203A HK1014935A1 (en) 1995-08-24 1998-12-30 Substituted benzylaminopiperidine compounds

Country Status (42)

Country Link
US (1) US6506775B1 (ro)
EP (2) EP1114817B1 (ro)
JP (1) JP3084069B2 (ro)
KR (1) KR100288673B1 (ro)
CN (1) CN1153764C (ro)
AP (1) AP643A (ro)
AR (1) AR006305A1 (ro)
AT (2) ATE258166T1 (ro)
AU (1) AU702698B2 (ro)
BG (1) BG64126B1 (ro)
BR (1) BR9609989A (ro)
CA (1) CA2227814C (ro)
CO (1) CO4480738A1 (ro)
CZ (1) CZ297543B6 (ro)
DE (2) DE69631390T2 (ro)
DK (2) DK0861235T3 (ro)
DZ (1) DZ2086A1 (ro)
ES (2) ES2211684T3 (ro)
HK (1) HK1014935A1 (ro)
HR (1) HRP960386B1 (ro)
HU (1) HU225480B1 (ro)
IL (1) IL119078A (ro)
IS (1) IS1947B (ro)
MA (1) MA23961A1 (ro)
MX (1) MX9801467A (ro)
MY (1) MY114800A (ro)
NO (1) NO310720B1 (ro)
NZ (1) NZ308207A (ro)
OA (1) OA10666A (ro)
PE (2) PE20010700A1 (ro)
PL (1) PL186773B1 (ro)
PT (2) PT861235E (ro)
RO (1) RO119299B1 (ro)
RU (1) RU2152930C2 (ro)
SI (2) SI0861235T1 (ro)
SK (1) SK282925B6 (ro)
TN (1) TNSN96107A1 (ro)
TR (1) TR199800300T1 (ro)
TW (1) TW340842B (ro)
UA (1) UA48981C2 (ro)
WO (1) WO1997008144A1 (ro)
YU (1) YU49122B (ro)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
EE200100586A (et) * 1999-05-06 2003-02-17 Pfizer Products Inc. Asendatud bensolaktaamühendid
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
AU775861B2 (en) 1999-05-21 2004-08-19 Pfizer Products Inc. 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
CN1777584A (zh) 2003-04-18 2006-05-24 伊莱利利公司 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
CA2566920A1 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine
MX2007000428A (es) 2004-07-15 2008-03-05 Amr Technology Inc Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
UA95454C2 (uk) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
EP2264029A4 (en) 2008-03-31 2011-08-24 Kowa Co 1,3-dihydroisobenzofuran DERIVATIVE
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
KR20120023072A (ko) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
MX2011011907A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2, 3,4-tetrahidroisoquinolina y uso de la misma.
MY174452A (en) 2009-10-14 2020-04-19 Schering Corp Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2011292261B2 (en) 2010-08-17 2015-05-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
IN2013MN02170A (ro) 2011-04-21 2015-06-12 Piramal Entpr Ltd
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
CZ289960B6 (cs) * 1991-03-26 2002-05-15 Pfizer Inc. Způsob přípravy substituovaných piperidinů
ES2092113T3 (es) * 1991-06-20 1996-11-16 Pfizer Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
EP0780375B1 (en) * 1995-12-21 2002-09-11 Pfizer Inc. 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
US6506775B1 (en) 2003-01-14
DK1114817T3 (da) 2004-04-26
HRP960386A2 (en) 1998-04-30
AU702698B2 (en) 1999-03-04
PL186773B1 (pl) 2004-02-27
EP1114817B1 (en) 2004-01-21
DZ2086A1 (fr) 2002-07-22
SK282925B6 (sk) 2003-01-09
PL325332A1 (en) 1998-07-20
OA10666A (en) 2002-11-25
TR199800300T1 (xx) 1998-06-22
PT1114817E (pt) 2004-05-31
CO4480738A1 (es) 1997-07-09
DE69616817D1 (de) 2001-12-13
SK20798A3 (en) 1999-03-12
KR100288673B1 (ko) 2001-05-02
ATE208377T1 (de) 2001-11-15
HUP9901159A3 (en) 2000-05-29
MA23961A1 (fr) 1997-04-01
JPH10510554A (ja) 1998-10-13
MY114800A (en) 2003-01-31
NO980751L (no) 1998-02-23
HRP960386B1 (en) 2002-04-30
NO980751D0 (no) 1998-02-23
RO119299B1 (ro) 2004-07-30
IS1947B (is) 2004-10-13
CZ297543B6 (cs) 2007-02-07
JP3084069B2 (ja) 2000-09-04
EP1114817A1 (en) 2001-07-11
YU49122B (sh) 2004-03-12
ES2163017T3 (es) 2002-01-16
IS4644A (is) 1997-12-30
HU225480B1 (en) 2006-12-28
MX9801467A (es) 1998-05-31
IL119078A0 (en) 1996-11-14
DE69631390D1 (de) 2004-02-26
EP0861235A1 (en) 1998-09-02
WO1997008144A1 (en) 1997-03-06
DE69616817T2 (de) 2002-04-04
HUP9901159A2 (hu) 1999-07-28
AR006305A1 (es) 1999-08-25
CA2227814C (en) 2002-12-31
NO310720B1 (no) 2001-08-20
DE69631390T2 (de) 2004-11-25
BR9609989A (pt) 1999-07-06
ATE258166T1 (de) 2004-02-15
BG64126B1 (bg) 2004-01-30
CA2227814A1 (en) 1997-03-06
KR19990044077A (ko) 1999-06-25
SI1114817T1 (en) 2004-06-30
RU2152930C2 (ru) 2000-07-20
PT861235E (pt) 2002-03-28
CZ52198A3 (cs) 1999-01-13
NZ308207A (en) 1998-07-28
AP643A (en) 1998-04-24
EP0861235B1 (en) 2001-11-07
TNSN96107A1 (fr) 2005-03-15
PE20010700A1 (es) 2001-07-09
AP9600850A0 (en) 1996-10-31
SI0861235T1 (en) 2002-04-30
CN1153764C (zh) 2004-06-16
BG102288A (en) 1998-09-30
DK0861235T3 (da) 2001-12-27
CN1193961A (zh) 1998-09-23
UA48981C2 (uk) 2002-09-16
PE1398A1 (es) 1998-02-27
AU5776996A (en) 1997-03-19
TW340842B (en) 1998-09-21
YU47896A (sh) 1998-12-23
ES2211684T3 (es) 2004-07-16
IL119078A (en) 2003-11-23

Similar Documents

Publication Publication Date Title
HRP960386B1 (en) Substituted benzylaminopiperidine compounds
GB9508810D0 (en) Compounds
GB9500691D0 (en) Compounds
GB9504910D0 (en) Compounds
GB9512129D0 (en) Compounds
GB9504948D0 (en) Compounds
GB9502540D0 (en) Compounds
GB9504990D0 (en) Compounds
GB9507290D0 (en) Compounds
GB9501581D0 (en) Compounds
GB9502782D0 (en) Compounds
GB9502783D0 (en) Compounds
GB9502784D0 (en) Compounds
GB9502785D0 (en) Compounds
GB9502983D0 (en) Compounds
GB9503211D0 (en) Compounds
GB9504190D0 (en) Compounds
GB9504801D0 (en) Compounds
GB9504802D0 (en) Compounds
GB9504803D0 (en) Compounds
GB9504907D0 (en) Compounds
GB9501471D0 (en) Compounds
GB9506168D0 (en) Compounds
GB9506169D0 (en) Compounds
GB9506703D0 (en) Compounds

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090610